Authors noted it may be worthwhile to explore whether oral methylphenidate affects myopia by influencing dopamine levels ...

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and ...

AAVB-039 advances gene therapy for Stargardt disease, aiming for innovative treatments for inherited retinal disorders.

The FDA accepted Aldeyra's resubmitted NDA for reproxalap after previous rejections due to efficacy concerns, despite no ...

A Chinese study reveals that secondhand smoke exposure significantly increases the risk of early-onset myopia in children ...

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...

The US Food and Drug Administration (FDA) recently granted fast track designation to Sanofi’s SAR446597 for the treatment of geographic atrophy (GA). 1 ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Krystal Biotech announced the first patient has been dosed in EMERALD-1, its phase 1/2 clinical trial evaluating KB801 for ...

Presentation highlights include 48-month data from the OAKS and DERBY trials as well as the GALE open-label extension.